23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
19:12 , Dec 15, 2016 |  BC Innovations  |  Product R&D

p53 and Ras: Back from the dead

After decades of research and countless failed attempts at drug development, industry is reviving its interest in two of oncology’s most intractable targets, p53 and Ras. While no one denies there’s still a long road...
08:00 , Feb 8, 2010 |  BioCentury  |  Product Development

Checking the boxes in gene therapy

Amsterdam Molecular Therapeutics thinks its Glybera represents the right combination of vector, gene and disease setting to become the first gene therapy to be approved outside of China. The European Medicines Agency now has accepted an...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Clinical News

Contusugene ladenovec regulatory update

EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen withdrew the application based on its "difficult financial situation." The...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

Advexin regulatory update

EMEA said Introgen withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to the agency, Introgen withdrew the application based on the company's "marketing strategy." Advexin, an adenovirus p53 tumor suppressor gene...
08:00 , Jan 5, 2009 |  BioCentury  |  Finance

Phase III & cash constrained

Phase III & cash constrained Company 3Q08 oper loss 9/30/08 cash Years cash Lead program Active Biotech (SSE:ACTI) (A) $9.0 $28.1 0.78 Anyara in...
08:00 , Jan 5, 2009 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30 10/8/08 Genmab (CSE:GEN) 16% to 540 ...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

Introgen cancer news

Introgen filed for Chapter 11 bankruptcy, retained Torreya Partners to explore strategic alternatives, and restructured and reduced headcount for the second time this year. The company reduced headcount by 30 (67%) to 15 to focus...
08:00 , Nov 24, 2008 |  BioCentury  |  Regulation

End of life candidates

End of life candidates Drug Company Indication First appraisal committee meeting Erbitux cetuximab ImClone (NASDAQ:IMCL)/Bristol-Myers (NYSE:BMY)/Merck KGaA (Xetra:MRK) Metastatic and/or recurrent squamous cell carcinoma of the head and neck...
07:00 , Oct 6, 2008 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1H08 operating loss 7/3/08 Introgen (NASDAQ:INGN) 28% to 50 $11.0 0.40 ...